FDA Inspection 1325092 — Clario (BioClinica, Inc.)
The FDA completed an inspection of Clario (BioClinica, Inc.) on Jun 25, 2026 in Philadelphia, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jun 25, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Philadelphia, PA (United States)